Xeris Pharmaceuticals | XERS - Beneficio Operativo





Beneficio Operativo Cambio Fecha
Celltrion KRW 13.72B 287.31B 2025-12
Cspc Pharmaceutical CNY 206.26M 1.02B 2025-12
Deva Holding AS TRY 964.87M 240.32M 2023-09
Dianthus Therapeutics USD -69.54M 29.25M 2025-12
Divis Laboratories Ltd INR 8.14B 420M 2026-03
Eli Lilly USD 9.78B 792M 2026-03
Kangmei Pharma CNY -10.94M 15.75M 2026-03
Knight Therapeutics CAD 6.21M 3.27M 2025-12
Laboratorios Farma EUR 135.05M 49.84M 2023-12
Malin Corporation EUR -1.1M 400K 2024-12
Medical Developments International AUD -36K 444K 2025-12
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Neuren Pharmaceuticals AUD 17.01M 11.56M 2025-12
Organigram Holdings CAD -20.13M 7.92M 2025-12
Ovoca Bio EUR -1.16M 4.48M 2025-06
Pacira USD 4.62M 1.43M 2026-03
Perrigo USD 33.6M 50.8M 2026-03
Pharma Mar EUR 622K 42.99M 2026-03
Qiagen NV USD 121.88M 15.41M 2025-12
Sartorius EUR 160.7M 9.5M 2026-03
Sino Biopharmaceutical CNY 5.18B 3.32B 2025-06
Supernus Pharmaceuticals USD -35.25M 49.07M 2026-03
Tilray USD -20.01M 9.34M 2025-09
Zealand Pharma A/S -707.05M 245.73M 2025-12
Zz Pientze Pharmaceu CNY 837.81M 336.48M 2026-03